Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses
Dione T. Kobayashi1*, Rory J. Olson2, Laurel Sly3, Chad J. Swanson1, Brett Chung1, Nikolai Naryshkin4, Jana Narasimhan4, Anuradha Bhattacharyya4, Michael Mullenix2, Karen S. Chen1
Sources: 1 Spinal Muscular Atrophy Foundation, New York, New York, United States of America, 2 Enzo Life Sciences Inc., Ann Arbor, Michigan, United States of America, 3 PharmOptima LLC, Portage, Michigan, United States of America, 4 PTC Therapeutics Inc., South Plainfield, New Jersey, United States of America
Kobayashi DT, Olson RJ, Sly L, Swanson CJ, Chung B, et al. (2011) Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses. PLoS ONE 6(8): e24269. doi:10.1371/journal.pone.0024269